Search

Your search keyword '"Cazzola, Mario"' showing total 289 results

Search Constraints

Start Over You searched for: Author "Cazzola, Mario" Remove constraint Author: "Cazzola, Mario" Database Academic Search Index Remove constraint Database: Academic Search Index
289 results on '"Cazzola, Mario"'

Search Results

1. Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.

2. Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database.

3. Hyperglycaemia and Chronic Obstructive Pulmonary Disease.

4. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.

5. Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?

6. Umeclidinio/vilanterolo nel trattamento farmacologico della BPCO.

7. Dual bronchodilation for the treatment of COPD: From bench to bedside.

9. Use of Thiols in the Treatment of COVID-19: Current Evidence.

10. Long‐acting muscarinic antagonists and small airways in asthma: Which link?

11. Treatable Mechanisms in Asthma.

12. Prospects for COPD treatment.

13. Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?

14. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.

15. Myelodysplastic Syndromes.

16. Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

18. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

19. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

20. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

21. Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators.

22. Impact of doxofylline in COPD: A pairwise meta-analysis.

23. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.

24. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.

25. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus.

26. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.

27. The Challenges of Precision Medicine in COPD.

28. Indacaterol/Glycopyrronium Combination for COPD.

29. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

30. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.

31. How I treat essential thrombocythemia.

33. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.

34. Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD.

35. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.

36. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues.

37. Interaction between corticosteroids and muscarinic antagonists in human airways.

40. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.

41. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.

42. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.

43. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.

44. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.

45. Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease.

48. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.

49. The genetic basis of myelodysplasia and its clinical relevance.

50. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease

Catalog

Books, media, physical & digital resources